|Other Names||Breast cancer metastasis-suppressor 1, BRMS1|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down- regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma.|
|Cellular Location||Nucleus. Cytoplasm. Note=Predominantly nuclear|
|Tissue Location||Expression levels are higher in term placentas than in early placentas. Low levels of expression observed in normal pregnancies and in molar pregnancies|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene reduces the metastatic potential, but not thetumorogenicity, of human breast cancer and melanoma cell lines. Theprotein encoded by this gene localizes primarily to the nucleus andis a component of the mSin3a family of histone deacetylasecomplexes (HDAC). The protein contains two coiled-coil motifs andseveral imperfect leucine zipper motifs. Alternative splicingresults in two transcript variants encoding different isoforms.
Wu, Y., et al. Cancer Lett. 293(1):82-91(2010)Vaidya, K.S., et al. Cancer Lett. 281(1):100-107(2009)Frolova, N., et al. Tumour Biol. 30(3):148-159(2009)Martins-de-Souza, D., et al. BMC Psychiatry 9, 17 (2009) :Cicek, M., et al. Clin. Exp. Metastasis 26(3):229-237(2009)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.